VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$5.93
+0.03 (+0.51%)
Open$5.85
Previous Close$5.90
Day High$6.00
Day Low$5.84
52W High$9.94
52W Low$4.14
Volume—
Avg Volume1.02M
Market Cap348.79M
P/E Ratio—
EPS$-4.05
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+160.5% upside
Current
$5.93
$5.93
Target
$15.45
$15.45
$11.33
$15.45 avg
$18.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 217.89M | 230.06M | 122.09M |
| Net Income | -222,302,246 | -211,246,987 | 12.67M |
| Profit Margin | -102.0% | -96.9% | 10.4% |
| EBITDA | -145,355,353 | -145,800,427 | 21.61M |
| Free Cash Flow | — | — | 20.08M |
| Rev Growth | -5.3% | -5.3% | +22.8% |
| Debt/Equity | 0.02 | 0.02 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |